Clinical study update UPPSALA, Sweden, Jan. 9, 2026 /PRNewswire/ -- Synartro is advancing the candidate drug SYN321, a novel intra-articular treatment for knee osteoarthritis, through a phase 1/2a clinical study focused on safety, tolerability, PK, and early efficacy signals. The study...
Hence then, the article about no serious adverse events to date in ongoing phase 1 2a clinical study of syn321 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( No serious adverse events to date in ongoing phase 1/2a clinical study of SYN321 )
Also on site :
- Several Denver-area gas stations pumped contaminated fuel this week, King Soopers warns
- Man police shot in Brooklyn hospital was former NYPD officer, police said
- Parker Waichman LLP Files Lawsuit on behalf of Chicago Resident in the Paragard MDL Alleging Injuries Caused by Breakage of the Copper IUD